Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/42516
MAIN B-CELL EPITOPES OF PVAMA-1 AND PVMSP-9 ARE TARGETED BY NATURALLY ACQUIRED ANTIBODIES AND EPITOPE-SPECIFIC MEMORY CELLS IN ACUTE AND CONVALESCENT PHASES OF VIVAX MALARIA
Author
Affilliation
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia. Juiz de Fora, MG, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Biofísica. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Laboratório de Tecnologia de Anticorpos Monoclonais. Rio de Janeiro, RJ, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Biofísica. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia. Juiz de Fora, MG, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Biofísica. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto de Tecnologia em Imunobiológicos. Laboratório de Tecnologia de Anticorpos Monoclonais. Rio de Janeiro, RJ, Brasil.
Universidade Federal de São Paulo. Escola Paulista de Medicina. Departamento de Biofísica. São Paulo, SP, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunoparasitologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal de Juiz de Fora. Instituto de Ciências Biológicas. Departamento de Parasitologia. Juiz de Fora, MG, Brasil.
Abstract
Although antibodies are considered critical for malaria protection, little is known about the mechanisms/factors that maintain humoral immunity, especially regarding the induction and maintenance of memory B cells over time. In Brazilian endemic areas, this is the first time that the profile of antibody responses and the occurrence of antigen-specific memory B cells (MBC) against P vivax were investigated during acute malaria and up to six months after parasite clearance. For this, we selected two peptides, PvAMA-1(S290-K307) and PvMSP-9(E795-A808) , which represent the apical membrane antigen-1 and merozoite surface protein-9 of P vivax, respectively. Both peptides were previously described as containing linear B-cell epitopes. Our findings were as follows: 1-both peptides were recognized by IgG antibodies at a high frequency (between 24% and 81%) in all study groups; 2-in the absence of infection, the IgG levels remained stable throughout 6 months of follow-up; and 3-PvAMA-1(S290-K307) and PvMSP-9(E795-A808) -specific MBCs were detected in all individual groups in the absence of reinfection throughout the follow-up period, suggesting long-lived MBC. However, no positive association was observed between malaria-specific antibody levels and frequency of MBCs over time. Taken together, these results suggest that peptides can be, in the future, an alternative strategy to polypeptidic vaccine formulation.
Share